Cargando…
Author Correction: The promise(s) of mesenchymal stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model systems
Autores principales: | Kotikalapudi, Nagasuryaprasad, Sampath, Samuel Joshua Pragasam, Sukesh Narayan, Sinha, R., Bhonde, Nemani, Harishankar, Mungamuri, Sathish Kumar, Venkatesan, Vijayalakshmi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479061/ https://www.ncbi.nlm.nih.gov/pubmed/34584190 http://dx.doi.org/10.1038/s41598-021-99380-z |
Ejemplares similares
-
The promise(s) of mesenchymal stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model systems
por: Kotikalapudi, Nagasuryaprasad, et al.
Publicado: (2021) -
Patient-derived xenografts: a promising resource for preclinical cancer research
por: Karamboulas, Christina, et al.
Publicado: (2019) -
Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2022) -
Promise(s) of Mesenchymal Stem Cells as an In Vitro Model System to Depict Pre-Diabetic/Diabetic Milieu in WNIN/GR-Ob Mutant Rats
por: Madhira, Soundarya L., et al.
Publicado: (2012) -
Author Correction: Volumetric MRI is a promising outcome measure of muscle reinnervation
por: Wilcox, Matthew, et al.
Publicado: (2021)